IL137384A0 - Bisulfate salt of hiv protease inhibitor - Google Patents

Bisulfate salt of hiv protease inhibitor

Info

Publication number
IL137384A0
IL137384A0 IL13738498A IL13738498A IL137384A0 IL 137384 A0 IL137384 A0 IL 137384A0 IL 13738498 A IL13738498 A IL 13738498A IL 13738498 A IL13738498 A IL 13738498A IL 137384 A0 IL137384 A0 IL 137384A0
Authority
IL
Israel
Prior art keywords
protease inhibitor
hiv protease
bisulfate salt
bisulfate
salt
Prior art date
Application number
IL13738498A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22104737&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL137384(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IL137384A0 publication Critical patent/IL137384A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL13738498A 1998-01-20 1998-12-22 Bisulfate salt of hiv protease inhibitor IL137384A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7196898P 1998-01-20 1998-01-20
PCT/US1998/027382 WO1999036404A1 (en) 1998-01-20 1998-12-22 Bisulfate salt of hiv protease inhibitor

Publications (1)

Publication Number Publication Date
IL137384A0 true IL137384A0 (en) 2001-07-24

Family

ID=22104737

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13738498A IL137384A0 (en) 1998-01-20 1998-12-22 Bisulfate salt of hiv protease inhibitor
IL137384A IL137384A (en) 1998-01-20 2000-07-19 Bisulfate salt of HIV protease inhibitor and medicinal preparations containing it

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL137384A IL137384A (en) 1998-01-20 2000-07-19 Bisulfate salt of HIV protease inhibitor and medicinal preparations containing it

Country Status (38)

Country Link
US (1) US6087383A (cs)
EP (1) EP1056722B1 (cs)
JP (2) JP4860037B2 (cs)
KR (1) KR100559283B1 (cs)
CN (1) CN1116282C (cs)
AR (1) AR014417A1 (cs)
AT (1) ATE219057T1 (cs)
AU (1) AU735875B2 (cs)
BG (1) BG64774B1 (cs)
BR (1) BR9814736A (cs)
CA (1) CA2317736C (cs)
CO (1) CO4970820A1 (cs)
CZ (1) CZ293507B6 (cs)
DE (1) DE69806067T2 (cs)
DK (1) DK1056722T3 (cs)
EE (1) EE04434B1 (cs)
EG (1) EG23936A (cs)
ES (1) ES2178300T3 (cs)
GE (1) GEP20033026B (cs)
HU (1) HU227196B1 (cs)
IL (2) IL137384A0 (cs)
LT (1) LT4780B (cs)
LV (1) LV12522B (cs)
MY (1) MY114838A (cs)
NO (1) NO315605B1 (cs)
NZ (1) NZ504417A (cs)
PE (1) PE20000185A1 (cs)
PL (1) PL190744B1 (cs)
PT (1) PT1056722E (cs)
RO (1) RO118869B1 (cs)
RU (1) RU2186070C2 (cs)
SK (1) SK283975B6 (cs)
TR (1) TR200001876T2 (cs)
TW (1) TW531531B (cs)
UA (1) UA59432C2 (cs)
UY (1) UY25345A1 (cs)
WO (1) WO1999036404A1 (cs)
ZA (1) ZA9956B (cs)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02012560A (es) 2000-06-30 2003-05-14 Elan Pharm Inc Compuestos para tratar la enfermedad de alzheimer.
JP2004534771A (ja) 2001-05-22 2004-11-18 イーラン　ファーマスーティカルズ、インコーポレイテッド アザヒドロキシル化エチルアミン化合物
US7157561B2 (en) * 2001-07-13 2007-01-02 Roche Diagnostics Operations, Inc. Methods of inhibiting transmission of a costimulatory signal of lymphocytes
US7193065B2 (en) * 2001-07-13 2007-03-20 Roche Diagnostics Operations, Inc. Protease inhibitor conjugates and antibodies useful in immunoassay
EP1585527A1 (en) * 2003-01-14 2005-10-19 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
TW200534879A (en) * 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
CN1980666B (zh) * 2004-05-04 2011-03-30 布里斯托尔-迈尔斯斯奎布公司 制备阿扎那韦硫酸氢盐的方法和新的形式
US20050256314A1 (en) * 2004-05-04 2005-11-17 Soojin Kim Process employing controlled crystallization in forming crystals of a pharmaceutical
US7829720B2 (en) * 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
US20050288343A1 (en) * 2004-05-19 2005-12-29 Andrew Rusowicz Process of preparing substituted carbamates and intermediates thereof
TWI415635B (zh) * 2004-05-28 2013-11-21 必治妥施貴寶公司 加衣錠片調製物及製備彼之方法
BRPI0518741A2 (pt) * 2004-12-03 2008-12-02 Merck & Co Inc uso de uma combinaÇço de uma droga diretamente metabolizada por ugt1a1 ou um seu sal farmaceuticamente aceitÁvel e atazanavir ou um seu sal farmaceuticamente aceitÁvel, e, combinaÇço farmacÊutica para administraÇço oral a um mamÍfero
US7642049B2 (en) 2006-06-30 2010-01-05 Bristol-Myers Squibb Company Method for identifying HIV-1 protease inhibitors with reduced metabolic affects through detection of human resistin polymorphisms
PT2069303E (pt) * 2006-07-21 2016-06-08 Gilead Sciences Inc Inibidores de protease antiviral
BG66056B1 (bg) * 2006-10-05 2010-12-30 Красимир ДЕЧЕВ Метод и инсталация за производство на трисезонна добавка към дизелово гориво
AR066972A1 (es) * 2007-06-12 2009-09-23 Concert Pharmaceuticals Inc Derivados azapeptidicos
US20100178340A1 (en) * 2007-06-22 2010-07-15 Bristol-Myers Squibb Company Tableted compositions containing atazanavir
HRP20110294T1 (hr) * 2007-06-22 2011-05-31 Bristol-Myers Squibb Company Smjese u obliku tablete koje sadržavaju atazanavir
KR20100033378A (ko) * 2007-06-22 2010-03-29 브리스톨-마이어스 스큅 컴퍼니 아타자나비르를 함유하는 정제 조성물
US20100183715A1 (en) * 2007-06-22 2010-07-22 Bristo-Meyers Squibb Company Tableted compositions containing atazanavir
AP2490A (en) * 2007-06-29 2012-10-04 Gilead Sciences Inc Therapeutic compositions and the use thereof
JP5547066B2 (ja) * 2007-06-29 2014-07-09 ギリアード サイエンシーズ， インコーポレイテッド 治療用組成物およびその使用
WO2009136365A1 (en) * 2008-05-08 2009-11-12 Ranbaxy Laboratories Limited Process for the preparation of 3,4-epoxy-2-amino-1-substituted butane derivatives and intermediate compounds thereof
US20120121722A1 (en) 2008-12-18 2012-05-17 Anup Avijit Choudhury Atazanavir formulations
WO2010079497A2 (en) * 2009-01-12 2010-07-15 Hetero Research Foundation Novel polymorph of atazanavir sulfate
WO2010138338A1 (en) 2009-05-27 2010-12-02 Merck Sharp & Dohme Corp. Hiv protease inhibitors
EP2272830A1 (en) 2009-06-18 2011-01-12 Esteve Química, S.A. Preparation process of an antivirally heterocyclic azahexane derivative
WO2011027324A1 (en) 2009-09-03 2011-03-10 Ranbaxy Laboratories Limited Polymorphic forms of atazanavir sulfate
WO2011053504A1 (en) 2009-10-26 2011-05-05 Merck Sharp & Dohme Corp. Solid pharmaceutical compositions containing an integrase inhibitor
WO2011080562A1 (en) 2009-12-29 2011-07-07 Hetero Research Foundation Novel aza-peptides containing 2,2-disubstituted cyclobutyl and/or substituted alkoxy benzyl derivatives as antivirals
DK2531027T3 (en) 2010-01-27 2015-07-20 Viiv Healthcare Co A therapeutic combination comprising dolutegravir, abacavir and lamivudine,
US20130005780A1 (en) 2010-03-01 2013-01-03 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
CN102917695A (zh) 2010-04-09 2013-02-06 百时美施贵宝公司 具有改进的pH效应的阿扎那韦硫酸盐制剂
EP2621472A1 (en) 2010-09-28 2013-08-07 Ratiopharm GmbH Dry processing of atazanavir
US20140343290A1 (en) 2011-07-27 2014-11-20 Rakesh Kumar Singh Process for the preparation of atazanavir or its bisulfate salt
US8461347B2 (en) 2011-08-05 2013-06-11 Scinopharm Taiwan, Ltd. Process for preparing form A of atazanavir sulfate
WO2013059928A1 (en) 2011-10-26 2013-05-02 Merck Canada Inc. Hiv protease inhibitors
EP2888230A4 (en) 2012-08-24 2017-07-19 Laurus Labs Private Limited Improved process for the preparation of atazanavir bisulfate
WO2014036690A1 (zh) * 2012-09-04 2014-03-13 上海迪赛诺化学制药有限公司 制备阿扎那韦硫酸氢盐a型结晶的方法
WO2014125270A1 (en) 2013-02-12 2014-08-21 Cipla House Process for preparing atazanavir sulphate
CN104250223B (zh) * 2013-06-28 2017-04-12 上海威智医药科技有限公司 阿扎那韦氢溴酸盐及其制备和应用
CN104250225A (zh) * 2013-06-28 2014-12-31 上海威智医药科技有限公司 阿扎那韦磷酸盐及其制备和应用
CN104250224A (zh) * 2013-06-28 2014-12-31 上海威智医药科技有限公司 阿扎那韦富马酸盐及其制备和应用
CN105859611A (zh) * 2016-04-18 2016-08-17 上海现代制药海门有限公司 一种阿扎那韦硫酸氢盐a型结晶的制备方法
CN109251165B (zh) * 2018-10-02 2022-09-23 国药集团川抗制药有限公司 阿扎那韦达二4-氨基苯磺酸盐及其制备方法
CN111349042B (zh) * 2018-12-20 2023-07-14 陕西理工大学 一种阿扎那韦单晶及其制备方法
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ248332A (en) * 1992-08-07 1995-01-27 Sankyo Co Hiv protease inhibitor and its use
TW409125B (en) * 1996-04-22 2000-10-21 Novartis Ag Antivirally active heterocyclic azahexane derivatives
US5849911A (en) * 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives

Also Published As

Publication number Publication date
PL342019A1 (en) 2001-05-07
ZA9956B (en) 2000-07-05
CA2317736A1 (en) 1999-07-22
JP2002509136A (ja) 2002-03-26
PL190744B1 (pl) 2006-01-31
CZ20002564A3 (cs) 2000-10-11
AU735875B2 (en) 2001-07-19
LV12522A (en) 2000-08-20
CO4970820A1 (es) 2000-11-07
RO118869B1 (ro) 2003-12-30
MY114838A (en) 2003-01-31
HK1033458A1 (en) 2001-08-31
HUP0101389A3 (en) 2003-07-28
CN1116282C (zh) 2003-07-30
US6087383A (en) 2000-07-11
AU2010199A (en) 1999-08-02
KR100559283B1 (ko) 2006-03-15
HK1033667A1 (en) 2001-09-14
SK10622000A3 (sk) 2001-02-12
CA2317736C (en) 2004-11-02
EE200000798A (et) 2002-06-17
HU227196B1 (en) 2010-10-28
KR20010034221A (ko) 2001-04-25
NZ504417A (en) 2001-09-28
UA59432C2 (uk) 2003-09-15
LV12522B (en) 2000-10-20
EP1056722A1 (en) 2000-12-06
NO20003692D0 (no) 2000-07-19
ATE219057T1 (de) 2002-06-15
EG23936A (en) 2008-01-14
BG64774B1 (bg) 2006-03-31
LT4780B (lt) 2001-04-25
RU2186070C2 (ru) 2002-07-27
PT1056722E (pt) 2002-09-30
CN1283188A (zh) 2001-02-07
IL137384A (en) 2006-08-01
EE04434B1 (et) 2005-02-15
LT2000067A (en) 2000-11-27
JP4860037B2 (ja) 2012-01-25
SK283975B6 (sk) 2004-06-08
CZ293507B6 (cs) 2004-05-12
HUP0101389A2 (hu) 2001-08-28
GEP20033026B (en) 2003-07-25
WO1999036404A1 (en) 1999-07-22
EP1056722B1 (en) 2002-06-12
DE69806067D1 (de) 2002-07-18
BR9814736A (pt) 2000-10-24
NO315605B1 (no) 2003-09-29
DE69806067T2 (de) 2003-01-23
EP1056722A4 (en) 2001-01-10
BG104618A (en) 2001-02-28
NO20003692L (no) 2000-07-19
TR200001876T2 (tr) 2000-11-21
ES2178300T3 (es) 2002-12-16
TW531531B (en) 2003-05-11
UY25345A1 (es) 2000-12-29
JP2009102357A (ja) 2009-05-14
DK1056722T3 (da) 2002-09-30
AR014417A1 (es) 2001-02-28
PE20000185A1 (es) 2000-05-14

Similar Documents

Publication Publication Date Title
IL137384A0 (en) Bisulfate salt of hiv protease inhibitor
PL349192A1 (en) Protease inhibitors
IL142398A0 (en) Serine protease inhibitor
ZA983629B (en) Serine protease inhibitors
PL343112A1 (en) Quinolones as serine protease inhibitors
EP0983228A4 (en) PROTEASE INHIBITORS
EP1093367A4 (en) PROTEASE INHIBITORS
PL337725A1 (en) Inhibitors of proteases
IL139187A0 (en) Cysteine protease inhibitors
EP1067894A4 (en) PROTHEASEINHIBITOREN
EP1079821A4 (en) PROTEASE INHIBITORS
GB9800817D0 (en) Serine protease inhibitors
PL342602A1 (en) Method of synthesising inhibitors of hiv protease
EP1086083A4 (en) PROTEASE INHIBITORS
EP1140897A4 (en) PROTEASE INHIBITORS
EP1015438A4 (en) PROTEASE INHIBITORS
ZA984514B (en) Hiv protease inhibitor
IL132998A0 (en) Vif-derived hiv protease inhibitors
EP0975612A4 (en) PROTEASE INHIBITORS
AU2001280634A1 (en) Salt forms of an hiv protease inhibitor
GB9714320D0 (en) Hiv protease inhibitor
AP9901648A0 (en) Hiv protease inhibitors
EP1195163A4 (en) Serine protease inhibitors
GB9814307D0 (en) Inhibition of serine proteases
HK1038559A (en) Serine protease inhibitor

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed